Application No.: 10/643581 Docket No.: HUI-041DV

LISTING OF CLAIMS

1. (Previously Presented) A method of identifying a compound that modulates hepatocyte growth or plasma cell differentiation or T cell subset activity comprising:

- a) contacting hepatocytes or B cells or T cells deficient in XBP-1 with a test compound; and
- b) determining the effect of the test compound on the growth of the hepatocytes or differentiation of the B cells into plasma cells or Th2 cytokine production by the T cells, the test compound being identified as a modulator of hepatocyte growth or plasma cell differentiation or T cell subset activity based on the ability of the test compound to modulate the growth of the hepatocytes or differentiation of the B cells or Th2 cytokine production by the T cells deficient in XBP-1.
- 2. (Previously Presented) The method of claim 1, wherein the cells deficient in XBP-1 are in a non-human XBP-1 deficient animal and the cells are contacted with the test compound by administering the test compound to the non-human XBP-1 deficient animal.
- 3. (Previously Presented) The method of claim 2, wherein the non-human XBP-1 deficient animal is a mouse.
- 4. (Previously Presented) The method of claim 1, wherein the cells deficient in XBP-1 are isolated from a non-human XBP-1 deficient animal, or embryo thereof, and the cells are contacted with the test compound by culturing the test compound with the isolated cells deficient in XBP-1.
- 5. (Previously Presented) The method of claim 1, wherein the compound stimulates hepatocyte growth or plasma cell differentiation or Th2 cytokine production
- 6. (Previously Presented) A method for modulating growth of hepatocytes or differentiation of plasma cells or T cell subset activity, comprising contacting hepatocytes or plasma cell precursors or T cells with a modulator of XBP-1 activity such that growth of the hepatocytes or differentiation of plasma cells or Th2 cytokine production by the T cells is modulated.

Application No.: 10/643581 Docket No.: HUI-041DV

7. (Previously Presented) The method of claim 6, wherein the modulator inhibits XBP-1 activity.

- 8. (Previously Presented) The method of claim 7, wherein the modulator is an antisense oligonucleotide.
- 9. (Previously Presented) The method of claim 7, wherein the modulator is an intracellular antibody.
- 10. (Previously Presented) The method of claim 6, wherein the modulator stimulates XBP-1 activity.
- 11. (Previously Presented) The method of claim 6, wherein the modulator is an expression vector encoding XBP-1.
- 12. (Previously Presented) The method of claim 6, wherein the hepatocytes or plasma cell precursors or T cells are contacted with the modulator by culturing the hepatocytes or plasma cell precursors or T cells *in vitro* with the modulator.
- 13. (Previously Presented) The method of claim 12, wherein the hepatocytes or plasma cell precursors or T cells are contacted with a modulator that stimulates XBP-1 activity such growth of the hepatocytes or differentiation of the plasma cell precursors into plasma cells or Th2 cytokine production by the T cells is stimulated, the method further comprising administering the hepatocytes or plasma cells or T cells to a subject after stimulation *in vitro*.